Trial Profile
Phase 1 open-label, dose escalation study of INB03 in patients with metastatic cancer with increased inflammatory biomarkers in peripheral blood
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 18 Apr 2022
Price :
$35
*
At a glance
- Drugs Pegipanermin (Primary)
- Indications Advanced breast cancer; Anal cancer; Cholangiocarcinoma; Colon cancer; Duodenal cancer; Gastric cancer; Gastrointestinal cancer; Lung cancer; Malignant melanoma; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Prostate cancer; Renal cancer; Solid tumours
- Focus Adverse reactions; Biomarker; First in man; Pharmacokinetics; Therapeutic Use
- Sponsors INmune Bio
- 17 Dec 2019 Results published in the Media Release
- 17 Dec 2019 According to an INmune Bio media release, the database of this trial has been locked.
- 24 Oct 2019 Status changed from recruiting to completed.